SCHEMBL29979438

SCHEMBL29979438

Cc1scnc1C1(CNC(=O)c2c(-c3ccccc3)cccc2S(C)(=O)=O)NC(=O)NC1=O

nearest known ligand 0.62

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ADAMTS7 Q9UKP4 17/20 0.62
ADAMTS4 O75173 3/20 0.36
MMP2 P08253 3/20 0.36
MMP3 P08254 3/20 0.36
MMP13 P45452 3/20 0.36
MMP14 P50281 3/20 0.36
ADAMTS5 Q9UNA0 3/20 0.36
ADAM17 P78536 2/20 0.33
MMP1 P03956 1/20 0.33
MMP7 P09237 1/20 0.33
MMP9 P14780 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29979374 0.88 ADAMTS7 (0.63) ADAMTS7ADAMTS4MMP2MMP3MMP13
SCHEMBL23367129 0.83 ADAMTS7 (0.76) ADAMTS7ADAMTS4MMP2MMP3MMP13
SCHEMBL29979411 0.82 ADAMTS7 (0.61) ADAMTS7ADAMTS4MMP2MMP3MMP13
SCHEMBL29979437 0.80 ADAMTS7 (0.60) ADAMTS7ADAMTS4MMP2MMP3MMP13
SCHEMBL30106306 0.80 ADAMTS7 (0.79) ADAMTS7ADAMTS4ADAMTS5ADAM17
SCHEMBL30106331 0.79 ADAMTS7 (0.78) ADAMTS7ADAMTS4ADAMTS5ADAM17
SCHEMBL30106299 0.79 ADAMTS7 (0.77) ADAMTS7ADAMTS4ADAMTS5ADAM17
SCHEMBL29979170 0.78 ADAMTS7 (0.80) ADAMTS7ADAMTS4MMP2MMP3MMP13
SCHEMBL23354223 0.78 ADAMTS7 (0.80) ADAMTS7ADAMTS4MMP2MMP3MMP13
SCHEMBL23354132 0.77 ADAMTS7 (0.58) ADAMTS7ADAMTS4MMP2MMP3MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 ADAMTS7 1/4885ADAMTS4 6/4885MMP2 137/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 ADAMTS7 1/4885ADAMTS4 6/4885MMP2 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.